Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU vs Irinotecan+Cisplatin vs S-1 in Advanced Gastric Cancer
NCT00142350Phase 3Completed
- Sponsor
- Japan Clinical Oncology Group
- Start
- Nov 2000
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tegafur, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and Cisplatin micelle injection (HA132) in gastric cancer (GC) (3 arms), sponsored by Japan Clinical Oncology Group. Primary endpoint: Overall Survival. Started Nov 2000; status: completed.
02
Drugs
tegafuririnotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabCisplatin micelle injection (HA132)
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00142350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00142350.